Large-scale testing (Phase 3)Study completedNCT04134728
What this trial is testing
Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors
Who this might be right for
Arthritis, Rheumatoid
GlaxoSmithKline 550